Literature DB >> 30852963

Cerebral Ischemia in Patients on Direct Oral Anticoagulants.

Kosmas Macha1, Armin Marsch1, Gabriela Siedler1, Lorenz Breuer1, Erwin F Strasser2, Tobias Engelhorn3, Stefan Schwab1, Bernd Kallmünzer1.   

Abstract

Background and Purpose- In patients with ischemic stroke on therapy with vitamin K antagonists, stroke severity and clinical course are affected by the quality of anticoagulation at the time of stroke onset, but clinical data for patients using direct oral anticoagulants (DOACs) are limited. Methods- Data from our registry including all patients admitted with acute cerebral ischemia while taking oral anticoagulants for atrial fibrillation between November 2014 and October 2017 were investigated. The activity of vitamin K antagonists was assessed using the international normalized ratio on admission and categorized according to a threshold of 1.7. DOAC plasma levels were measured using the calibrated Xa-activity (apixaban, rivaroxaban, and edoxaban) or the Hemoclot-assay (dabigatran) and categorized into low (<50 ng/mL), intermediate (50-100 ng/mL), or high (>100 ng/mL). Primary objective was the association between anticoagulant activity and clinical and imaging characteristics. Results- Four hundred sixty patients were included (49% on vitamin K antagonists and 51% on DOAC). Patients on vitamin K antagonists with low international normalized ratio values had higher scores on the National Institutes of Health Stroke Scale and a higher risk of large vessel occlusion on admission. For patients on DOAC, plasma levels were available in 75.6% and found to be low in 49 (27.7%), intermediate in 41 (23.2%), and high in 87 patients (49.2%). Low plasma levels were associated with higher National Institutes of Health Stroke Scale scores on admission (low: 8 [interquartile range, 3-15] versus intermediate: 4 [1-11] versus high: 3 [0-8]; P<0.001) and higher risk of persisting neurological deficits or cerebral infarction on imaging (85.7% versus 75.6% versus 54.0%; P<0.001). Low DOAC plasma levels were an independent predictor of large vessel occlusion (odds ratio, 3.84 [95% CI, 1.80-8.20]; P=0.001). Conclusions- The activity of anticoagulation measured by specific DOAC plasma levels on admission is associated with stroke severity and presence of large vessel occlusion.

Entities:  

Keywords:  anticoagulants; atrial fibrillation; direct oral anticoagulants; ischemic stroke; plasma level

Mesh:

Substances:

Year:  2019        PMID: 30852963     DOI: 10.1161/STROKEAHA.118.023877

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).

Authors:  Amichai Perlman; Maor Wanounou; Rachel Goldstein; Lotan Choshen Cohen; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.

Authors:  Adela-Nicoleta Roşian; Ştefan Horia Roşian; Bela Kiss; Maria Georgia Ştefan; Adrian Pavel Trifa; Camelia Diana Ober; Ovidiu Anchidin; Anca Dana Buzoianu
Journal:  Genes (Basel)       Date:  2020-04-17       Impact factor: 4.096

3.  A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting.

Authors:  Galit H Frydman; Felix Ellett; Elizabeth M Van Cott; Douglas Hayden; Maulik Majmudar; Charles R Vanderburg; Haley Dalzell; Divya L Padmanabhan; Nick Davis; Julianne Jorgensen; Mehmet Toner; James G Fox; Ronald G Tompkins
Journal:  Crit Care Explor       Date:  2019-08-20

4.  Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity.

Authors:  Timolaos Rizos; Andreas D Meid; Andrea Huppertz; Chris Dumschat; Jan Purrucker; Kathrin I Foerster; Jürgen Burhenne; David Czock; Ekkehart Jenetzky; Peter A Ringleb; Walter E Haefeli
Journal:  J Stroke       Date:  2022-01-31       Impact factor: 6.967

5.  Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.

Authors:  Shin-Yi Lin; Ching-Hua Kuo; Shin-Joe Yeh; Li-Kai Tsai; Yen-Bin Liu; Chih-Fen Huang; Sung-Chun Tang; Jiann-Shing Jeng
Journal:  Clin Pharmacol Ther       Date:  2019-09-14       Impact factor: 6.875

6.  Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.

Authors:  Svenja Stoll; Kosmas Macha; Armin Marsch; Stefan T Gerner; Gabriela Siedler; Kilian Fröhlich; Bastian Volbers; Erwin F Strasser; Stefan Schwab; Bernd Kallmünzer
Journal:  J Neurol       Date:  2020-03-23       Impact factor: 4.849

7.  Long-Term Anticoagulation in Secondary Ischemic Stroke Prevention: The Prospective Multicenter RESTAIC Registry.

Authors:  Raquel Gutiérrez-Zúñiga; Ricardo Rigual; Gabriel Torres-Iglesias; Sara Sánchez-Velasco; María Alonso de Leciñana; Jaime Masjuan; Rodrigo Álvarez Velasco; Inmaculada Navas; Laura Izquierdo-Esteban; José Fernández-Ferro; Jorge Rodríguez-Pardo; Gerardo Ruiz-Ares; Gustavo Zapata-Wainberg; Blanca Fuentes; Exuperio Díez-Tejedor
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003

8.  Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants.

Authors:  Jan C Purrucker; Kyra Hölscher; Jennifer Kollmer; Peter A Ringleb
Journal:  J Clin Med       Date:  2020-09-11       Impact factor: 4.241

9.  Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation.

Authors:  Thomas R Meinel; Mattia Branca; Gian Marco De Marchis; Krassen Nedeltchev; Timo Kahles; Leo Bonati; Marcel Arnold; Mirjam R Heldner; Simon Jung; Emmanuel Carrera; Elisabeth Dirren; Patrik Michel; Davide Strambo; Carlo W Cereda; Giovanni Bianco; Georg Kägi; Jochen Vehoff; Mira Katan; Manuel Bolognese; Roland Backhaus; Stephan Salmen; Sylvan Albert; Friedrich Medlin; Christian Berger; Ludwig Schelosky; Susanne Renaud; Julien Niederhauser; Christophe Bonvin; Michael Schaerer; Marie-Luise Mono; Biljana Rodic; Alexander A Tarnutzer; Pasquale Mordasini; Jan Gralla; Johannes Kaesmacher; Stefan Engelter; Urs Fischer; David J Seiffge
Journal:  Ann Neurol       Date:  2020-10-17       Impact factor: 10.422

10.  Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study.

Authors:  Amichai Perlman; Rachel Goldstein; Lotan Choshen Cohen; Bruria Hirsh-Raccah; David Hakimian; Ilan Matok; Yosef Kalish; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2021-02-17       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.